Evotec stock falls after weak quarterly loss widens

Published on 09/08/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock is under pressure as recent Q2 2026 figures show a widening loss per share and the price drifting close to its 52-week low, keeping investors focused on profitability and analyst expectations.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) is trading lower on September 8, 2026, with the share recently quoted around 3.15 EUR on Xetra after intraday losses of about 1.9 percent, keeping the biotech group under pressure near its 52-week low.finanzen.ch The latest move comes in the wake of Evotec's second-quarter 2026 results, which confirmed a widening loss per share and reinforced investor concerns around the company’s path back to sustainable profitability.finanzen.ch

Quarterly loss per share deepens

According to market data summarizing Evotec's Q2 2026 figures presented on August 13, 2026, the company reported a loss of 0.26 EUR per share for the quarter ended June 30, 2026, compared with a loss of 0.24 EUR per share in the same quarter a year earlier, meaning the quarterly loss per share increased by about 8.3 percent year on year.finanzen.ch This progression underscores that, despite ongoing collaborations and a diversified pipeline, Evotec has not yet managed to reverse its negative earnings trend at the bottom line.

Analysts cited by the same overview expect Evotec to post a full-year 2026 loss of 1.297 EUR per share, highlighting that markets currently anticipate continued red ink for the current fiscal year rather than a quick return to profitability.finanzen.ch For investors, the key question is how quickly management can leverage its discovery and development platforms into higher-margin revenue streams that close the gap between research spending and operating income.

Stock trades close to 52-week low

Intraday data from Xetra on September 8, 2026, show Evotec stock recently down 1.9 percent at 3.15 EUR at around 16:28 local time, after opening the session at 3.19 EUR and touching an intraday low of 3.13 EUR.finanzen.ch Trading volume reached 572,284 shares, pointing to active trading in the name as investors digest the latest quarterly numbers and re-evaluate their exposure.finanzen.ch

The technical picture remains fragile: Evotec shares fell to 3.12 EUR on September 2, 2026, marking their lowest level in 52 weeks.finanzen.ch With the current Xetra price only about 1.0 percent to 2.0 percent above that 52-week low, the stock is effectively trading at the bottom of its one-year range, underlining how much value has eroded for long-term holders over the past years.finanzen.ch A separate performance review notes that at a close of 3.21 EUR on September 7, 2026, a ten-year investment in Evotec had shrunk by 29.61 percent, illustrating the persistent challenge the company faces in creating shareholder value over extended periods.finanzen.ch

Analyst stance and risk focus

Despite the depressed share price, Evotec still retains some support among analysts: coverage from RBC Capital Markets lists the stock with an Outperform rating as of August 13, 2026, indicating that at least one major house sees upside potential from current levels.finanzen.ch However, the Outperform stance is balanced by the reality that both recent quarterly results and the consensus for fiscal year 2026 still point to losses, so the case for the stock depends heavily on future execution rather than current profitability.

The principal risk factor for Evotec stock in this setting is the continued negative earnings profile combined with a share price pressed against its 52-week low, which can limit financial flexibility and investor patience if progress toward break-even remains slower than expected.finanzen.ch Investors also need to consider that, in an environment where broader European indices are described as subdued amid macro uncertainty, select growth and biotech names like Evotec can become more sensitive to changes in risk appetite and funding conditions.The Business Times

Drug discovery platform and partnerships

Evotec SE, based in Germany, operates as a drug discovery and development company, running integrated platforms that span early discovery through to preclinical and, in some collaborations, clinical development. The group works primarily as a partner for pharmaceutical and biotechnology companies, offering services such as hit identification, lead optimization, and translational research, frequently under long-term collaboration agreements that can include milestone payments and potential royalties.

A core element of Evotec's business model is its focus on building a pipeline of partnered and proprietary projects across therapeutic areas including neurology, metabolic diseases, and oncology. For investors, this means the revenue base is diversified across multiple alliances, but it also implies that spending on research and development is structurally high, which can weigh on short-term earnings metrics like EPS until individual projects reach more lucrative stages of development or commercialization.

Evotec stock price and investor takeaway

As of September 8, 2026, Evotec stock is quoted at about 3.15 EUR on its primary listing on Xetra, down roughly 1.9 percent from the previous close and trading just above its 52-week low of 3.12 EUR, with intraday volume at more than 570,000 shares.finanzen.ch With Q2 2026 EPS at a loss of 0.26 EUR versus a loss of 0.24 EUR in the prior-year quarter and analysts still forecasting a full-year 2026 loss, the stock remains a story of long-term pipeline potential weighed against near-term profitability risks.finanzen.ch For investors, the current price level near the bottom of the one-year range makes the timing of any operational turnaround particularly decisive.